Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/OARRR.S169152 http://scihub22266oqcxt.onion/10.2147/OARRR.S169152 C6037273!6037273 !30013407     free     free     free       Open+Access+Rheumatol 2018 ; 10 (?): 97-101 Nephropedia Template TP {{tp|p=30013407 |t=2018. Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate |pdf=|usr=}}{{30013407 }} gab.com Text Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate JO: Open Access Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=30013407 #FOAvip PURPOSE: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. PATIENTS AND METHODS: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). RESULTS: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). CONCLUSION: MTX is underused in the treatment of RA in the USA. Twit Text FOAVip Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate ????Open Access Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=30013407 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30013407 #FOAvip English Wikipedia <ref>{{Cite pmid|30013407 }}</ref> Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate #MMPMID30013407 O'Dell JR ; Cohen SB ; Thorne JC ; Kremer J Open Access Rheumatol 2018[]; 10 (?): 97-101 PMID30013407 show ga PURPOSE: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. PATIENTS AND METHODS: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). RESULTS: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). CONCLUSION: MTX is underused in the treatment of RA in the USA. ?Treatment of rheumatoid arthritis in the USA: premature use of tumor n(epmc).pdf DeepDyve Pubget Overpricing